Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
Authors
Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
Brian Lee Claggett, Pardeep S. Jhund, John J.V. McMurray, Alasdair Henderson et al.
Citations
7 citations
Journal
European Journal of Heart Failure
Topics
Heart Failure Treatment and Management
Field-Weighted Citation Impact (FWCI)
9.72
article
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
Brian Lee Claggett, Pardeep S. Jhund, John J.V. McMurray, Alasdair Henderson, Jawad H. Butt, Faiez M. Zannad, Muthiah Vaduganathan, Carolyn S.P. Lam, Bertram Pitt, Katharina Mueller, Adriaan A. Voors, Sanjiv J. Shah, Akshay S. Desai, Scott D Solomon, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
European Journal of Heart FailureVol. 27(8)
Institutions
Northwestern University (US), Brigham and Women's Hospital (US), Harvard University (US), Bayer (United States) (US), National University of Singapore (SG), University of Groningen (NL), University of Michigan (US), British Heart Foundation (GB), Ospedale Papa Giovanni XXIII (IT), National University Heart Centre Singapore (SG), National Heart Centre Singapore (SG), Bay Medical Center (US), University of Milano-Bicocca (IT), Bayer (Germany) (DE), University of Glasgow (GB), Université de Lorraine (FR)
Funders
Amgen, Eli Lilly and Company, AstraZeneca, Bayer, Sanofi, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Boston Scientific Corporation, Regeneron Pharmaceuticals, Cytokinetics, Sarepta Therapeutics, Fresenius Medical Care North America, MyoKardia, Impulse Dynamics, Moderna, British Heart Foundation, University of Glasgow, Daiichi-Sankyo, Novo Nordisk, Idorsia Pharmaceuticals, Intas Pharmaceuticals, National Institutes of Health, Chugai Pharmaceutical, Sanofi Pasteur, American Regent, Respicardia, Relypsa, National Heart, Lung, and Blood Institute